PURA syndrome-causing mutations impair PUR-domain integrity and affect P-body association.
PURA
PURA syndrome
RNA binding
X-ray crystallography
cell biology
human
molecular biophysics
protein folding stability
structural biology
Journal
eLife
ISSN: 2050-084X
Titre abrégé: Elife
Pays: England
ID NLM: 101579614
Informations de publication
Date de publication:
24 Apr 2024
24 Apr 2024
Historique:
medline:
24
4
2024
pubmed:
24
4
2024
entrez:
24
4
2024
Statut:
epublish
Résumé
Mutations in the human PURA syndrome is a neurodevelopmental disorder that affects about 650 patients worldwide, resulting in a range of symptoms including neurodevelopmental delays, intellectual disability, muscle weakness, seizures, and eating difficulties. The condition is caused by a mutated gene that codes for a protein called PURA. PURA binds RNA – the molecule that carries genetic information so it can be translated into proteins – and has roles in regulating the production of new proteins. Contrary to other conditions that result from mutations in a single gene, PURA syndrome patients show ‘high penetrance’, meaning almost every reported mutation in the gene leads to symptoms. Proske, Janowski et al. wanted to understand the molecular basis for this high penetrance. To find out more, the researchers first examined how patient mutations affected the location of the PURA in the cell, using human cells grown in the laboratory. Normally, PURA travels to P-bodies, which are groupings of RNA and proteins involved in regulating which genes get translated into proteins. The researchers found that in cells carrying PURA syndrome mutations, PURA failed to move adequately to P-bodies. To find out how this ‘mislocalization’ might happen, Proske, Janowski et al. tested how different mutations affected the three-dimensional folding of PURA. These analyses showed that the mutations impair the protein’s folding and thereby disrupt PURA’s ability to bind RNA, which may explain why mutant PURA cannot localize correctly. Proske, Janowski et al. describe the molecular abnormalities of PURA underlying this disorder and show how molecular analysis of patient mutations can reveal the mechanisms of a disease at the cell level. The results show that the impact of mutations on the structural integrity of the protein, which affects its ability to bind RNA, are likely key to the symptoms of the syndrome. Additionally, their approach used establishes a way to predict and test mutations that will cause PURA syndrome. This may help to develop diagnostic tools for this condition.
Autres résumés
Type: plain-language-summary
(eng)
PURA syndrome is a neurodevelopmental disorder that affects about 650 patients worldwide, resulting in a range of symptoms including neurodevelopmental delays, intellectual disability, muscle weakness, seizures, and eating difficulties. The condition is caused by a mutated gene that codes for a protein called PURA. PURA binds RNA – the molecule that carries genetic information so it can be translated into proteins – and has roles in regulating the production of new proteins. Contrary to other conditions that result from mutations in a single gene, PURA syndrome patients show ‘high penetrance’, meaning almost every reported mutation in the gene leads to symptoms. Proske, Janowski et al. wanted to understand the molecular basis for this high penetrance. To find out more, the researchers first examined how patient mutations affected the location of the PURA in the cell, using human cells grown in the laboratory. Normally, PURA travels to P-bodies, which are groupings of RNA and proteins involved in regulating which genes get translated into proteins. The researchers found that in cells carrying PURA syndrome mutations, PURA failed to move adequately to P-bodies. To find out how this ‘mislocalization’ might happen, Proske, Janowski et al. tested how different mutations affected the three-dimensional folding of PURA. These analyses showed that the mutations impair the protein’s folding and thereby disrupt PURA’s ability to bind RNA, which may explain why mutant PURA cannot localize correctly. Proske, Janowski et al. describe the molecular abnormalities of PURA underlying this disorder and show how molecular analysis of patient mutations can reveal the mechanisms of a disease at the cell level. The results show that the impact of mutations on the structural integrity of the protein, which affects its ability to bind RNA, are likely key to the symptoms of the syndrome. Additionally, their approach used establishes a way to predict and test mutations that will cause PURA syndrome. This may help to develop diagnostic tools for this condition.
Identifiants
pubmed: 38655849
doi: 10.7554/eLife.93561
pii: 93561
doi:
pii:
Substances chimiques
DNA-Binding Proteins
0
RNA-Binding Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : Ni-1110/6-2
Informations de copyright
© 2024, Proske, Janowski et al.
Déclaration de conflit d'intérêts
MP, RJ, SB, HK, TM, TK, SH, JT, AC, LM, AV, RF, ED, GD, DD, MS, DN No competing interests declared
Références
EMBO J. 2020 Jan 2;39(1):e101112
pubmed: 31721251
J Cell Biol. 1995 Sep;130(5):1171-9
pubmed: 7657701
Brain Sci. 2022 Jun 30;12(7):
pubmed: 35884678
Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32
pubmed: 15572765
Hum Mol Genet. 2012 Feb 1;21(3):473-84
pubmed: 22010047
J Comput Chem. 2004 Jul 15;25(9):1157-74
pubmed: 15116359
Acta Crystallogr D Biol Crystallogr. 2011 Apr;67(Pt 4):235-42
pubmed: 21460441
Bioinformatics. 2015 Apr 15;31(8):1325-7
pubmed: 25505092
Acta Neuropathol. 2018 Mar;135(3):427-443
pubmed: 29302778
Acta Crystallogr D Biol Crystallogr. 2006 Jan;62(Pt 1):72-82
pubmed: 16369096
Mol Cell Biol. 1992 Mar;12(3):1257-65
pubmed: 1545807
J Med Genet. 2018 Feb;55(2):104-113
pubmed: 29097605
Acta Crystallogr D Biol Crystallogr. 2010 Jan;66(Pt 1):12-21
pubmed: 20057044
Acta Crystallogr D Biol Crystallogr. 1997 May 1;53(Pt 3):240-55
pubmed: 15299926
Eur J Hum Genet. 2023 Jan;31(1):112-121
pubmed: 36376392
Gene. 1998 Mar 27;210(1):37-44
pubmed: 9524214
EMBO J. 2012 Nov 14;31(22):4258-75
pubmed: 22968170
Cell. 2018 Jan 25;172(3):590-604.e13
pubmed: 29373831
Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18521-6
pubmed: 19846792
Nucleic Acids Res. 2023 Feb 22;51(3):1297-1316
pubmed: 36651277
Mol Biol Cell. 2017 Jun 1;28(11):1412-1417
pubmed: 28404748
J Cell Physiol. 1999 Oct;181(1):160-8
pubmed: 10457364
J Cell Biochem. 2001;80(4):589-95
pubmed: 11169743
PLoS One. 2010 Oct 14;5(10):e13402
pubmed: 20976240
Proc Natl Acad Sci U S A. 2013 May 7;110(19):7778-83
pubmed: 23553836
J Med Genet. 2014 Dec;51(12):806-13
pubmed: 25342064
Mol Cell Biol. 1993 May;13(5):3103-12
pubmed: 7682655
J Chem Theory Comput. 2009 Jun 9;5(6):1632-9
pubmed: 26609855
Mol Cell Biol. 2003 Oct;23(19):6857-75
pubmed: 12972605
Cell. 2018 Apr 19;173(3):706-719.e13
pubmed: 29677514
Biochem Biophys Res Commun. 2000 Oct 22;277(2):341-7
pubmed: 11032728
J Clin Invest. 2015 Aug 3;125(8):2914-23
pubmed: 26237041
Nucleic Acids Res. 2007;35(6):e45
pubmed: 17317681
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):125-32
pubmed: 20124692
Acta Neuropathol. 2016 Apr;131(4):605-20
pubmed: 26728149
J Neurosci Res. 2006 May 1;83(6):929-43
pubmed: 16511857
J Chem Theory Comput. 2014 May 13;10(5):2064-9
pubmed: 26580533
Am J Med Genet A. 2018 Jan;176(1):56-67
pubmed: 29150892
Front Genet. 2021 Mar 11;12:638217
pubmed: 33777106
Elife. 2013 Sep 10;2:e01456
pubmed: 24040512
J Cell Biochem. 2001 Aug 21-Sep 5;83(3):355-63
pubmed: 11596104
RNA Biol. 2020 Sep;17(9):1228-1238
pubmed: 32476604
J Cell Sci. 2015 May 1;128(9):1787-99
pubmed: 25788698
Neurol Genet. 2021 Nov 15;7(6):e613
pubmed: 34790866
Am J Hum Genet. 2014 Nov 6;95(5):579-83
pubmed: 25439098
Science. 2013 Mar 15;339(6125):1335-8
pubmed: 23393093
Neurotox Res. 2018 May;33(4):693-701
pubmed: 28975482
Protein Expr Purif. 2005 May;41(1):207-34
pubmed: 15915565